Welcome
Registration is NOW CLOSED for the 2025 Garrod Symposium.
Please email askcpd@mcmaster.ca with questions.
​
This year's event will be held at the
University of British Columbia, Vancouver, BC.
​
This program is approved as an Accredited Group Learning Activity (Section 1) as defined by the MOC Program of the RCPSC. A maximum of 13.5 MOC Section 1 hours has been approved.
Photo credit to Geoff Lister
Target Audience
Physicians, Laboratorians, Researchers, Registered Nurses, Genetic Counsellors, Registered Dietitians, Clinical Specialists, Laboratory Technicians and Trainees.
Anticipated 2025 Attendance
At the 2025 Garrod Symposium, we are planning for:​
-
An in-person meeting with opportunities to interact with attendees.
-
150–175 delegates from mostly across Canada and the United States.
-
We expect the delegates to be physicians, laboratorians, genetic counsellors, registered dietitians, researchers, clinical specialists, trainees, other health professionals and industry.
The annual Garrod Symposium brings together Canadian and International experts with active clinical, research and educational roles in the field of inborn errors of metabolism (IEM). Attendees represent a broad range of expertise, including clinical and laboratory metabolic specialists, geneticists, dieticians, nurses, genetic counselors and basic science researchers.
The theme of this year’s meeting is “Precision therapy and biomarkers in IMDs, from cellular models to clinical trials”, with a wide range of topics of interest for clinicians, scientists, and trainees.
Learning Objectives
By the end of this activity, participants will be able to:
-
Explain the role of cellular models in the preclinical stages of drug design and orphan drug development.
-
Describe the process of biomarker development for clinical trials, including limitations and challenges to their development.
-
Evaluate the impact of novel therapies, new screening technologies, patient advocacy, and new biomarker discoveries on driving recommendations for newborn screening.
-
Assess novel clinical trial designs, recent advances and failures in gene therapy, ethical considerations, and the importance of registries and natural history studies, and integrate these insights integrate into research and clinical practice.
-
Discuss the role and impact of Artificial intelligence in precision treatment of inborn metabolic disorders.
